MONDAY, SEPTEMBER 26, 2016

Johnson & Johnson steps up Ebola response

Johnson & Johnson announced on Thursday that it will accelerate the development of its Ebola virus treatment regimen.

The regimen, which incorporates technology from Crucell and Bavarian Nordic, uses a prime-boost regimen, in which one vector primes and the other boosts a patient's immune response.

Johnson & Johnson also said on Thursday that it will collaborate with global response to provide immediate relief to address the current Ebola outbreak in West Africa.

"Our primary goal in this escalating Ebola epidemic is to assist governments in protecting health care workers, families and populations who are at high risk of being infected with Ebola as soon as possible in an effort to stop the disease from spreading further," Paul Stoffels, the chief scientific officer at Johnson & Johnson, said. "With a strong heritage in collaborative partnerships and a proven track record in the rapid development and access of innovative products, we aim to ultimately eradicate deadly diseases like Ebola and save lives around the world."

The company's accelerated response to the ongoing Ebola virus outbreak in West Africa is aligned with the World Health Organization's roadmap to combat the disease. The plan calls for increased access to Ebola treatments and vaccines.

Crucell and Bavarian Nordic are also currently developing preventative vaccines for filoviruses, which include Ebola.